Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) said its board has approved the first grants under its 2025 A Share Option Scheme and 2025 H Share RSU Scheme, according to Tuesday's Hong Kong bourse filings.

Hong Kong-listed shares of the firm were down nearly 1% in Wednesday morning trade.

Under the A Share Option Scheme, the company granted 4.54 million A share options to 195 participants at an exercise price of 27.93 yuan per share, representing about 0.17% of Fosun Pharma's issued share capital as of Nov. 4.

Separately, the H Share RSU First Grant involved 10.59 million restricted share units awarded to 195 grantees, including six executive directors and senior management members, based on a closing price of HK$22.62 per H share on the grant date.

Following the grants, 43.51 million H shares remain available for future awards under the H Share Scheme mandate limit, representing about 8.1% of total H shares in issue, the filing said.